成人急性髓系白血病新的基因突变与预后相关性研究进展

周念; 胡建达

doi:10.13201/j.issn.1004-2806.2014.01.023

成人急性髓系白血病新的基因突变与预后相关性研究进展

周念^1,2,3,
胡建达^1,2,3, ,

- 福建医科大学协和临床医学院, 福建医科大学附属协和医院血液科, 福建省血液病研究所(福州, 350001)

详细信息

通讯作者: 胡建达,E-mail:jdhu@medmail.com.cn

中图分类号: R733.71

收稿日期: 2012-12-05

Research progress on new gene mutations and their prognostic significance in adult acute myeloid leukemia

ZHOU Nian^1,2,3,
HU Jianda^1,2,3, ,

More Information

Corresponding author: HU Jianda, E-mail: jdhu@medmail.com.cn

Received Date: 05 December 2012

摘要

- 白血病,髓系,急性 /
- 基因突变 /
- 预后
Abstract: Acute myeloid leukemia (AML) is a class of heterogeneous disease,cytological and molecular cytogenetic abnormalities are important factors affecting the prognosis.With the increase of molecular diagnostic techniques,many significant genetic changes are found such as DNMT3A,IDH1,IDH2,TET2 and ASXL1 and so on,which result in the heterogeneity of AML prognosis. Research on the earlier found gene mutations such as FLT3 and CEBPA also has new discoveries.This gene level assessment provides an important basis for prognostic stratification therapy in AML patients.In this paper,research progress on these new gene mutations and their prognostic significance in adult AML are reviewed.
- acute myeloid leukemia /
- gene mutation /
- prognosis

HTML全文

参考文献(39)

[1]	LEY T J,DING L,WALTER M J,et al.DNMT3A mutations in acute myeloid leukemia[J].N Engl J Med,2010,363:2424-2433.
[2]	HOU H A,KUO Y Y,LIU C Y,et al.DNMT3A mutations in acute myeloid leukemia:stability during disease evolution and clinical implications[J].Blood,2012,119:559-568.
[3]	RIBEIRO A F,PRATCORONA M,ERPELINCK-VERSCHUEREN C,et al.Mutant DNMT3A:a marker of poor prognosis in acute myeloid leukemia[J].Blood,2012,119:5824-5831.
[4]	SHEN Y,ZHU YM,FAN X,et al.Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia[J].Blood,2011,118:5593-5603.
[5]	MARCUCCI G,METZELER K H,SCHWIND S,et al.Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia[J].J Clin Oncol,2012,30:742-750.
[6]	MARKOVA J,MICHKOVA P,BURCKOVA K,et al.Prognostic impact of DNMT3A mutations in patients with intermediate cytogenetic risk profile acute myeloid leukemia[J].Eur J Haematol,2012,88:128-135.
[7]	PATEL J P,GÖNEN M,FIGUEROA M E,et al.Prognostic relevance of integrated genetic profiling in acute myeloid leukemia[J].N Engl J Med,2012,366:1079-1089.
[8]	SCHNITTGER S,HAFERLACH C,ULKE M,et al.IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status[J].Blood,2010,116:5486-5496.
[9]	RAVANDI F,PATEL K,LUTHRA R,et al.Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin[J].Cancer,2012,118:2665-2673.
[10]	GREEN C L,EVANS C M,HILLS R K,et al.The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status[J].Blood,2010,116:2779-2782.
[11]	NOMDEDEU J,HOYOS M,CARRICONDO M,et al.Adverse impact of IDH1 and IDH2 mutations in primary AML:experience of the Spanish CETLAM group[J].Leuk Res,2012,36:990-997.
[12]	WAGNER K,DAMM F,GOHRING G,et al.Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia:SNP rs11554137 is an adverse prognostic factor[J].J Clin Oncol,2010,28:2356-2364.
[13]	CHOU W C,LEI W C,KO B S,et al.The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia[J].Leukemia,2011,25:246-253.
[14]	BOISSEL N,NIBOUREL O,RENNEVILLE A,et al.Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia:a study by the Acute Leukemia French Association group[J].J Clin Oncol,2010,28:3717-3723.
[15]	GREEN C L,EVANS C M,ZHAO L,et al.The prognostic significance of IDH2 mutations in AML depends on the location of the mutation[J].Blood,2011,118:409-412.
[16]	CHOU W C,CHOU S C,LIU CY,et al.TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics[J].Blood,2011,118:3803-3810.
[17]	KOSMIDER O,DELABESSE E,DE MAS V M,et al.TET2 mutations in secondary acute myeloid leukemias:a French retrospective study[J].Haematologica,2011,96:1059-1063.
[18]	GAIDZIK V I,PASCHKA P,SPATH D,et al.TET2 mutations in acute myeloid leukemia (AML):results from a comprehensive genetic and clinical analysis of the AML study group[J].J Clin Oncol,2012,30:1350-1357.
[19]	魏计锋,陈广华,仇惠英,等.急性髓系白血病患者TET2基因突变发生率及其临床意义[J].中华血液学杂志,2011,32(5):304-307.
[20]	METZELER K H,MAHARRY K,RADMACHER M D,et al.TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia:a Cancer and Leukemia Group B study[J].J Clin Oncol,2011,29:1373-1381.
[21]	CHOU W C,HUANG H H,HOU H A,et al.Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1(ASXL1) mutations[J].Blood,2010,116:4086-4094.
[22]	PRATCORONA M,ABBAS S,SANDERS M A,et al.Acquired mutations in ASXL1 in acute myeloid leukemia:prevalence and prognostic value[J].Haematologica,2012,97:388-392.
[23]	METZELER K H,BECKER H,MAHARRY K,et al.ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category[J].Blood,2011,118:6920-6929.
[24]	AWAD M M,ALADLE D A,ABOUSAMRA N K,et al.CEBPA gene mutations in Egyptian acute myeloid leukemia patients:impact on prognosis[J].Hematology,2013,18:61-68.
[25]	DUFOUR A,SCHNEIDER F,HOSTER E,et al.Monoallelic CEBPA mutations in normal karyotype acute myeloid leukemia:independent favorable prognostic factor within NPM1 mutated patients[J].Ann Hematol,2012,91:1051-1063.
[26]	GREIF P A,DUFOUR A,KONSTANDIN N P,et al.GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia[J].Blood,2012,120:395-403.
[27]	FASAN A,EDER C,HAFERLACH C,et al.GATA2 mutations are frequent in intermediate-risk karyotype AML with biallelic CEBPA mutations and are associated with favorable prognosis[J].Leukemia,2013,27:482-485.
[28]	SCHLENK R F,DOHNER K,KRAUTER J,et al.Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia[J].N Engl J Med,2008,358:1909-1918.
[29]	SCHNEIDER F,HOSTER E,SCHNEIDER S,et al.Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML(NK-AML)[J].Ann Hematol,2012,91:9-18.
[30]	KRÖNKE J,SCHLENK R F,JENSEN K O,et al.Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia:a study from the German-Austrian acute myeloid leukemia study group[J].J Clin Oncol,2011,29:2709-2716.
[31]	SCHNITTGER S,BACHER U,KERN W,et al.Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia[J].Leukemia,2011,25:1297-1304.
[32]	SCHNEIDER F,HOSTER E,UNTERHALT M,et al.The FLT3ITD mRNA level has a high prognostic impact in NPM1 mutated,but not in NPM1 unmutated AML with a normal karyotype[J].Blood,2012,119:4383-4386.
[33]	SANTOS F P,JONES D,QIAO W,et al.Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia[J].Cancer,2011,117:2145-2155.
[34]	HOU H A,HUANG T C,LIN LI,et al.WT1 mutation in 470 adult patients with acute myeloid leukemia:stability during disease evolution and mplication of its incorporation into a survival scoring system[J].Blood,2010,115:5222-5231.
[35]	GAIDZIK V I,SCHLENK R F,MOSCHNY S,et al.Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia:a study of the German-Austrian AML Study Group[J].Blood,2009,113:4505-4511.
[36]	DAMM F,HEUSER M,MORGAN M,et al.Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in cytogenetically normal acute myeloid leukemia[J].J Clin Oncol,2010,28:578-585.
[37]	CHOI Y,LEE J H,HUR E H,et al.Single nucleotide polymorphism of Wilms' tumor 1 gene rs16754 in Korean patients with cytogenetically normal acute myeloid leukemia[J].Ann Hematol,2012,91:671-677.
[38]	MENDLER J H,MAHARRY K,RADMACHER M D,et al.RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and microRNA expression signatures[J].J Clin Oncol,2012,30:3109-3118.
[39]	GAIDZIK V I,BULLINGER L,SCHLENK R F,et al.RUNX1 mutations in acute myeloid leukemia:results from a comprehensive genetic and clinical analysis from the AML study group[J].J Clin Oncol,2011,29:1364-1372.